Anticoagulant effects of hirulog, ∗∗Hirulog™ brand direct thrombin inhibitor. a novel thrombin inhibitor, in patients with coronary artery disease
Christopher P. Cannon(Brigham and Women's Hospital), Peter Ganz(University of Pisa), Arthur McAllister(Harvard University), Karen Eddings(Brigham and Women's Hospital), Burt Adelman(Massachusetts General Hospital), Dorinda George(Brigham and Women's Hospital), John M. Maraganore(Biogen (United States)), Andrew P. Selwyn(Biogen (United States)), Irving H. Fox(University of Michigan–Ann Arbor), Eugene Braunwald(University of Houston), Joseph Loscalzo(Brigham and Women's Hospital)
Cited by 82
Related Papers
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2011|1.9k
Circadian Variation in the Frequency of Onset of Acute Myocardial Infarction
|New England Journal of Medicine|1985|1.9k